Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 17/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 10/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1913174 | 0.89 | DPP4 (0.38) | DPP4DPP8LMNADPP9MEN1 | |
| SCHEMBL339713 | 0.83 | DPP4 (0.40) | DPP4DPP8DPP9CYP1A2CYP3A4 | |
| SCHEMBL868834 | 0.82 | DPP4 (0.39) | DPP4DPP8DPP9CYP1A2CYP3A4 | |
| SCHEMBL339714 | 0.82 | DPP4 (0.45) | DPP4DPP8DPP9CYP1A2CYP3A4 | |
| SCHEMBL340037 | 0.81 | DPP4 (0.39) | DPP4DPP8LMNADPP9 | |
| SCHEMBL339884 | 0.81 | CYP3A4 (0.40) | DPP4DPP8DPP9CYP1A2CYP3A4 | |
| SCHEMBL340191 | 0.81 | LMNA (0.42) | DPP4DPP8LMNADPP9CYP3A4 | |
| SCHEMBL340138 | 0.80 | DPP4 (0.41) | DPP4DPP8DPP9CYP1A2CYP3A4 | |
| SCHEMBL340137 | 0.80 | DPP4 (0.39) | DPP4DPP8DPP9CYP1A2CYP3A4 | |
| SCHEMBL339141 | 0.80 | DPP4 (0.43) | DPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077787-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-03-29 | — | — | US | disclosed |
| US-8097617-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-01-17 | — | — | US | disclosed |
| US-20090253689-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-10-08 | — | — | US | disclosed |
| EP-2004643-A1 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007113226-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077787-A1 | ORGANIC COMPOUNDS | OAT, GPR119, OTC | DPP4 120/4885DPP8 403/4885LMNA 3629/4885 |
| US-20090253689-A1 | Organic Compounds | OAT, GPR119, OTC | DPP4 120/4885DPP8 403/4885LMNA 3629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.